4//SEC Filing
MISSLING CHRISTOPHER U 4
Accession 0001731122-25-000096
CIK 0001314052other
Filed
Jan 16, 7:00 PM ET
Accepted
Jan 17, 9:14 PM ET
Size
8.3 KB
Accession
0001731122-25-000096
Insider Transaction Report
Form 4
MISSLING CHRISTOPHER U
DirectorPresident and CEO
Transactions
- Award
Stock Option (Right to Buy)
2025-01-15+166,666→ 166,000 totalExercise: $7.54From: 2025-01-15Exp: 2032-06-14→ Common Stock (166,000 underlying) - Award
Stock Option (Right to Buy)
2025-01-15+125,000→ 125,000 totalExercise: $8.57From: 2025-01-15Exp: 2032-06-14→ Common Stock (125,000 underlying)
Footnotes (2)
- [F1]On June 14, 2022, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in three equal tranches based on performance milestones, one of which was completion of Phase 2b/3 study for Alzheimer's disease. The performance criteria for this milestone was met with the final publication of all clinical trial data, resulting in vesting of the option as to 166,000 shares.
- [F2]On March 31, 2023, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was Publication of AD-004 Alzheimer's disease study. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares.
Documents
Issuer
ANAVEX LIFE SCIENCES CORP.
CIK 0001314052
Entity typeother
Related Parties
1- filerCIK 0001196573
Filing Metadata
- Form type
- 4
- Filed
- Jan 16, 7:00 PM ET
- Accepted
- Jan 17, 9:14 PM ET
- Size
- 8.3 KB